leukemia after failure of first-line imatinib: a randomized phase 2 trial Dasatinib or high-dose imatinib for chronic-phase chronic myeloid

doi:10.1182/blood-2006-11-056028Prepublished online February 22, 2007;2007 109: 5143-5150€€€€and Neil ShahHellmann, Andrey Zaritsky, Anatoly Golenkov, Jerald Radich, Timothy Hughes, Athena CountouriotisSaengsuree Jootar, Tadeusz Robak, Nina Khoroshko, Tamas Masszi, Aleksander Skotnicki, Andrzej Hagop Kantarjian, Ricardo Pasquini, Nelson Hamerschlak, Philippe Rousselot, Jerzy Holowiecki,€

[1]  M. Litzow.  Imatinib resistance: obstacles and opportunities. , 2009, Archives of pathology & laboratory medicine.

[2]  R. Larson,et al.  Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. , 2007, Blood.

[3]  M. Baccarani,et al.  Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. , 2007, Blood.

[4]  M. Baccarani,et al.  Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. , 2007, Blood.

[5]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[6]  H. Kantarjian,et al.  Dynamics of molecular response to dasatinib (BMS-354825) in patients (pts) with chronic myelogenous leukemia (CML) resistant or intolerant to imatinib. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Larson,et al.  Dasatanib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are imatinib (IM)-resistant (IM-R) or intolerant (IM-I): The CA180015 'START-L' study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Susan O'Brien,et al.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.

[9]  M. Wittekind,et al.  The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. , 2006, Cancer research.

[10]  Moshe Talpaz,et al.  Dasatinib (BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion and Induces Cell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinoma and Non–Small Cell Lung Cancer Cells , 2005, Clinical Cancer Research.

[11]  B. Druker,et al.  Combined Abl Inhibitor Therapy for Minimizing Drug Resistance in Chronic Myeloid Leukemia: Src/Abl Inhibitors Are Compatible with Imatinib , 2005, Clinical Cancer Research.

[12]  C. Sawyers,et al.  A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant chronic phase chronic myeloid leukemia (CML): Results from CA180002 , 2005 .

[13]  Susan O'Brien,et al.  Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate , 2005, Clinical Cancer Research.

[14]  Ping Chen,et al.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.

[15]  C. Sawyers,et al.  Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials. , 2004 .

[16]  J. Tokarski,et al.  The Crystal Structure of Abl Kinase with BMS-354825, a Dual SRC/ABL Kinase Inhibitor. , 2004 .

[17]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[18]  F. Guilhot.  Indications for imatinib mesylate therapy and clinical management. , 2004, The oncologist.

[19]  A. Hochhaus,et al.  Clinical resistance to imatinib: mechanisms and implications. , 2004, Hematology/oncology clinics of North America.

[20]  H. Kantarjian,et al.  High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. , 2004, Blood.

[21]  D. Marin,et al.  Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. , 2003, Blood.

[22]  J. Zonder,et al.  The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  R. Clark,et al.  The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia , 2003, British journal of haematology.

[24]  H. Kantarjian,et al.  Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. , 2003, Blood.

[25]  N. Shah.  Loss of response to imatinib: mechanisms and management. , 2005, Hematology. American Society of Hematology. Education Program.